4D Pharma begins Thetanix phase 1 clinical trial
Pharmaceutical company 4D pharma has begun dosing in a phase 1 clinical trial with Thetanix for the treatment of Paediatric Crohn's disease (PCD).
4D Pharma
16.66p
16:30 10/02/23
0.00%
0.00p
FTSE AIM 100
3,527.89
16:39 14/11/24
n/a
n/a
FTSE AIM 50
3,970.79
16:39 14/11/24
n/a
n/a
FTSE AIM All-Share
729.82
16:39 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
PCD is a rare chronic inflammatory bowel disease that is caused by the malfunction of the immune system leading to inflammation, or swelling, across the lining of the digestive tract.